Who's Topping the Digital Charts? - Summary - MDSpire

Who's Topping the Digital Charts?

  • By

  • Helen Bristow

  • May 21, 2026

Share

Objective:

To provide comprehensive insights into the digital pathology market and assist healthcare providers in making informed technology purchasing decisions.

Key Findings:
  • Only 15% of US healthcare providers have adopted digital pathology, with most using it minimally.
  • European countries have higher adoption rates, exceeding 50%, with specific examples of leading countries.
  • KLAS reports provide independent benchmarking data on major vendors in the US market, including specific vendor names.
Interpretation:

The digital pathology market is still in its infancy in the US, with significant growth potential but also considerable challenges related to adoption, implementation, and user resistance.

Limitations:
  • The report may not cover all vendors or capture every aspect of user experience, and user feedback may vary based on their level of experience with digital pathology.
  • Adoption barriers are complex and vary by institution.
Conclusion:

KLAS reports serve as a valuable resource for labs considering digital pathology, helping them navigate vendor options and implementation challenges while addressing the credibility gap between vendor claims and real-world performance.

Original Source(s)

Who's Topping the Digital Charts?

  • by Helen Bristow

  • May 21, 2026

Related Content

FDA Approves Expanded Liquid Biopsy Panel

Updated liquid biopsy combines genomic and epigenomic profiling for companion diagnostic use across multiple tumor types.

Digital Pathology: the Great Translation Debate

Conference discussions highlighted collaboration, resilience, and the realities of AI adoption in pathology labs

DNA Quality Outweighs Bone Source

Background DNA burden was more strongly associated with sequencing profile completeness than bone source in unidentified human remains.